Group One Trading
REGN icon

Group One Trading’s Regeneron Pharmaceuticals REGN Stock Holding History

Group One Trading’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Sell
3,668
-1,731
-32% -$1.18M ﹤0.01% 2099
2026
Q1 		$4.17M Buy
5,399
+2,207
+69% +$1.69M 0.01% 1446
2025
Q4 		$2.46M Sell
3,192
-557
-15% -$378K ﹤0.01% 2095
2025
Q3 		$2.11M Buy
+3,749
New +$2.12M ﹤0.01% 2272
2025
Q2 		– Sell
-765
Closed -$427K – 8543
2025
Q1 		$485K Buy
+765
New +$526K ﹤0.01% 3112
2020
Q4 		– Sell
-956
Closed -$516K – 6917
2020
Q3 		$535K Buy
+956
New +$580K ﹤0.01% 2782
2016
Q2 		– Sell
-1,089
Closed -$393K – 4889
2016
Q1 		$393K Hold
1,089
– – 0.01% 1851
2015
Q4 		$591K Buy
+1,089
New +$590K 0.01% 1689
2014
Q1 		– Sell
-305
Closed -$84K – 5512
2013
Q4 		$84K Sell
305
-100
-25% -$28.8K ﹤0.01% 3190
2013
Q3 		$127K Sell
405
-4,697
-92% -$1.24M ﹤0.01% 2807
2013
Q2 		$1.15M Buy
+5,102
New +$1.19M 0.03% 724

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Group One Trading's REGN Position: Q2 2026 in Review

Group One Trading reduced its Regeneron Pharmaceuticals (REGN) stake by 32% in Q2 2026, selling an estimated $1.18M and leaving 3,668 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2099.

Group One Trading first reported a position in REGN in Q2 2013 and has held it in 11 quarters since. The position peaked at $4.17M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Group One Trading held 3,668 shares of Regeneron Pharmaceuticals worth $2.29M as of Q2 2026.
  • Group One Trading sold 1,731 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.18M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #2099 holding.
  • Group One Trading first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 11 quarters since.
  • Group One Trading's Regeneron Pharmaceuticals position peaked at $4.17M in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.